Alembic Ltd
Alembic Limited is engaged in the businesses of Pharmaceuticals, Real Estate, and Power Assets. The company was started in 1907 as the flagship company of the Alembic Group. In 2010, the company demerged its core pharmaceutical business (formulations) into a wholly-owned subsidiary, Alembic Pharma Ltd and after the demerger, APL became the flagship company of the Alembic Group.
With its registered office in Vadodra, Alembic Ltd currently holds a 28.41% stake in Alembic Pharma Ltd and a 19.01% stake in another group entity Paushak Limited.[1]
- Market Cap ₹ 2,381 Cr.
- Current Price ₹ 92.7
- High / Low ₹ 109 / 70.5
- Stock P/E 7.43
- Book Value ₹ 95.2
- Dividend Yield 2.59 %
- ROCE 6.07 %
- ROE 13.0 %
- Face Value ₹ 2.00
Pros
- Company has reduced debt.
- Company is almost debt free.
- Stock is trading at 0.97 times its book value
- Market value of investments Rs.3,886 Cr. is more than the Market Cap Rs.2,381 Cr.
- Company has been maintaining a healthy dividend payout of 20.7%
Cons
- Company has a low return on equity of 13.1% over last 3 years.
- Earnings include an other income of Rs.75.3 Cr.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Consumer Discretionary Realty Realty Residential, Commercial Projects
Part of BSE Consumer Discretionary BSE 1000
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 144 | 134 | 147 | 125 | 124 | 74 | 74 | 78 | 127 | 157 | 222 | 240 | 239 | |
| 134 | 128 | 140 | 114 | 106 | 71 | 62 | 64 | 87 | 101 | 128 | 150 | 153 | |
| Operating Profit | 10 | 6 | 7 | 11 | 18 | 3 | 11 | 14 | 40 | 57 | 94 | 90 | 86 |
| OPM % | 7% | 4.6% | 4.6% | 9% | 15% | 4.4% | 15% | 18% | 32% | 36% | 42% | 38% | 36% |
| 21 | 25 | 25 | 37 | 29 | 93 | 10 | 89 | 54 | 55 | 75 | 73 | 75 | |
| Interest | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 2 | 2 |
| Depreciation | 6 | 6 | 5 | 4 | 3 | 3 | 4 | 5 | 7 | 8 | 11 | 12 | 13 |
| Profit before tax | 23 | 25 | 27 | 44 | 45 | 93 | 17 | 98 | 87 | 103 | 156 | 149 | 146 |
| Tax % | -3% | 2% | -3% | 5% | 8% | 0% | 19% | 12% | 7% | 10% | 7% | 15% | |
| 107 | 235 | 145 | 163 | 213 | 329 | 343 | 222 | 191 | 269 | 311 | 317 | 321 | |
| EPS in Rs | 3.99 | 8.78 | 5.45 | 6.10 | 8.30 | 12.82 | 13.35 | 8.65 | 7.42 | 10.46 | 12.10 | 12.36 | 12.48 |
| Dividend Payout % | 4% | 2% | 4% | 3% | 2% | 5% | 2% | 21% | 30% | 23% | 20% | 19% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 6% |
| 5 Years: | 27% |
| 3 Years: | 24% |
| TTM: | 8% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 3% |
| 5 Years: | -2% |
| 3 Years: | 16% |
| TTM: | 1% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 12% |
| 5 Years: | -1% |
| 3 Years: | 5% |
| 1 Year: | -12% |
| Return on Equity | |
|---|---|
| 10 Years: | 14% |
| 5 Years: | 11% |
| 3 Years: | 13% |
| Last Year: | 13% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 53 | 53 | 53 | 53 | 51 | 51 | 51 | 51 | 51 | 51 | 51 | 51 |
| Reserves | 474 | 750 | 858 | 1,032 | 1,157 | 1,367 | 2,246 | 2,445 | 2,027 | 2,134 | 2,287 | 2,394 |
| 0 | 9 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 9 | 14 | 11 | |
| 91 | 64 | 81 | 73 | 57 | 53 | 112 | 135 | 127 | 134 | 150 | 134 | |
| Total Liabilities | 619 | 875 | 992 | 1,159 | 1,266 | 1,471 | 2,409 | 2,632 | 2,205 | 2,329 | 2,503 | 2,590 |
| 169 | 146 | 171 | 179 | 209 | 225 | 265 | 297 | 321 | 369 | 409 | 472 | |
| CWIP | 2 | 0 | 0 | 0 | 0 | 3 | 6 | 0 | 0 | 1 | 0 | 2 |
| Investments | 299 | 605 | 732 | 913 | 1,001 | 1,133 | 2,047 | 2,208 | 1,754 | 1,786 | 1,900 | 1,974 |
| 149 | 124 | 89 | 67 | 55 | 110 | 91 | 127 | 130 | 173 | 194 | 142 | |
| Total Assets | 619 | 875 | 992 | 1,159 | 1,266 | 1,471 | 2,409 | 2,632 | 2,205 | 2,329 | 2,503 | 2,590 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 22 | 10 | 52 | 24 | 22 | 7 | -2 | -18 | 39 | 23 | 86 | 120 | |
| 5 | -5 | -47 | -22 | 68 | 57 | -35 | 19 | 7 | 26 | -27 | -54 | |
| -25 | -5 | -5 | -3 | -89 | -6 | -15 | -6 | -46 | -48 | -58 | -68 | |
| Net Cash Flow | 2 | -0 | -0 | -1 | 1 | 57 | -52 | -5 | -0 | 0 | 1 | -1 |
| Free Cash Flow | 22 | 11 | 38 | 14 | -1 | -15 | -49 | -51 | 14 | -33 | 36 | 43 |
| CFO/OP | 222% | 172% | 771% | 245% | 145% | 246% | 0% | -63% | 112% | 39% | 109% | 154% |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 122 | 76 | 54 | 74 | 40 | 44 | 69 | 71 | 67 | 46 | 49 | 49 |
| Inventory Days | 880 | 659 | 438 | 247 | 289 | 411 | 2,112 | 2,885 | 3,694 | 1,161 | ||
| Days Payable | 200 | 144 | 128 | 125 | 202 | 151 | 693 | 640 | 1,237 | 530 | ||
| Cash Conversion Cycle | 801 | 591 | 364 | 195 | 126 | 305 | 1,488 | 2,316 | 67 | 2,502 | 49 | 679 |
| Working Capital Days | 235 | 172 | 39 | 20 | 13 | 22 | 97 | 223 | 118 | 77 | 57 | -6 |
| ROCE % | 4% | 4% | 4% | 4% | 7% | 1% | 4% | 4% | 5% | 7% | 6% |
Insights
In beta| Mar 2016 | Mar 2017 | Mar 2020 | Mar 2021 | Sep 2022 | Mar 2025 | |
|---|---|---|---|---|---|---|
| Stake in Alembic Pharmaceuticals Limited % ・Standalone data |
|
|||||
| Co-generation power installed capacity MW ・Standalone data |
||||||
| Land bank acres ・Standalone data |
||||||
| Wind power installed capacity MW ・Standalone data |
||||||
| Permanent workforce count ・Standalone data |
||||||
| Real estate project bookings % ・Standalone data |
||||||
| R&D Expenditure (Percentage of Turnover) % ・Standalone data |
||||||
Extracted by Screener AI
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
- Newspaper cuttings related to advertisement published for Unaudited Financial Results of the Company for the Quarter ended on 30th June, 2026, in Indian Express ....
- Proceedings Of The 119Th Annual General Meeting Held On 11Th August, 2026
- Shareholder Meeting / Postal Ballot-Outcome of AGM
- Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
- Paper cuttings of newspaper advertisement issued regarding another special window opened for transfer and dematerialization of physical securities.
Annual reports
-
Annual Report 2026
from bse
-
Annual Report 2025
from bse
-
Annual Report 2024
from bse
-
Annual Report 2023
from bse
-
Annual Report 2022
from bse
-
Annual Report 2021
from bse
-
Annual Report 2020
from bse
-
Annual Report 2019
from bse
-
Annual Report 2018
from bse
-
Annual Report 2017
from bse
-
Annual Report 2016
from bse
-
Annual Report 2015
from bse
-
Annual Report 2014
from bse
-
Annual Report 2013
from bse
-
Annual Report 2012
from bse
Business Segments:[1]
a) Real Estate (81% in FY26 vs 85% in FY25):[2]
The company develops residential and commercial real estate projects, provides
project management and marketing consultancy services and generates rental income by leasing commercial properties.